
    
      Secondary objectives are to assess and compare the safety and efficacy of study treatments
      therapy in both study arms on non-relapse mortality (NRM), relapse-free survival (RFS),
      Overall survival (OS), QOL, toxicity, development of acute and chronic GvDH as well as
      engraftment and chimerism and impact of measurable residual disease.
    
  